• Submit to Viruses Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• About
• Open Access Policy

• Abstract
• Full-Text PDF [596 KB]

• Article Statistics
• PubMed/Medline
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Le Tortorec, A
• Willey, S
• Neil, S
• [+] on Google Scholar
• Le Tortorec, A
• Willey, S
• Neil, S
• [+] on PubMed
• Le Tortorec, A
• Willey, S
• Neil, S

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter

This article is

• freely available
• re-usable

Viruses 2011, 3(5), 520-540; doi:10.3390/v3050520

Review

Antiviral Inhibition of Enveloped Virus Release by Tetherin/BST-2: Action and Counteraction

Anna Le Tortorec ^† , Suzanne Willey ^†  and Stuart J. D. Neil*

Department of Infectious Disease, King’s College London School of Medicine, Guy’s Hospital, London SE1 9RT, UK ^† These authors contributed equally to this manuscript.

* Author to whom correspondence should be addressed.

Received: 18 March 2011; in revised form: 19 April 2011 / Accepted: 28 April 2011 / Published: 6 May 2011

(This article belongs to the Special Issue Antiviral Innate Immunity)

Download PDF Full-Text [596 KB, uploaded 6 May 2011 14:43 CEST]

Abstract: Tetherin (BST2/CD317) has been recently recognized as a potent interferon-induced antiviral molecule that inhibits the release of diverse mammalian enveloped virus particles from infected cells. By targeting an immutable structure common to all these viruses, the virion membrane, evasion of this antiviral mechanism has necessitated the development of specific countermeasures that directly inhibit tetherin activity. Here we review our current understanding of the molecular basis of tetherin’s mode of action, the viral countermeasures that antagonize it, and how virus/tetherin interactions may affect viral transmission and pathogenicity.

Keywords: Tetherin/BST2; restriction of enveloped virus release; interferon; viral countermeasure; Vpu

Article Statistics

Cite This Article